1-Sulfonyl-4-acylpiperazines as Selective Cannabinoid-1 Receptor (CB1R) Inverse Agonists for the Treatment of Obesity

详细信息    查看全文

• 作者：Petr Vachal ; Joan M. Fletcher ; Tung M. Fong ; Cathy C. R.-R. Huang ; Julie Lao ; Jing C. Xiao ; Chun-Pyn Shen ; Alison M. Strack ; Lauren Shearman ; Sloan Stribling ; Richard Z. Chen ; Andrea Frassetto ; Xinchu
• 刊名：Journal of Medicinal Chemistry
• 出版年：2009
• 出版时间：April 23, 2009
• 年：2009
• 卷：52
• 期：8
• 页码：2550-2558
• 全文大小：349K
• 年卷期：v.52,no.8(April 23, 2009)
• ISSN：1520-4804

文摘

A novel series of 1-sulfonyl-4-acylpiperazines as selective cannabinoid-1 receptor (CB1R) inverse agonists was discovered through high throughput screening (HTS) and medicinal chemistry lead optimization. Potency and in vivo properties were systematically optimized to afford orally bioavailable, highly efficacious, and selective CB1R inverse agonists that caused food intake suppression and body weight reduction in diet-induced obese rats and dogs. It was found that the receptor binding assay predicted in vivo efficacy better than functional antagonist/inverse agonist activities. This observation expedited the structure−activity relationship (SAR) analysis and may have implications beyond the series of compounds presented herein.